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a b s t r a c t
IVIG is frequently used in the ‘pre-conditioning’ regimens for higher risk transplants; its effects are
attributed in part to induction of Tregs. We have identiﬁed regulatory T cell (Treg) epitopes, now known
as Tregitopes, in IgG, the main component of intravenous immunoglobulin therapy (IVIg). Tregitopes pro-
vide one explanation for the expansion and activation of Treg cells following IVIg treatment. Tregitopes
are peptides that exhibit high afﬁnity binding to multiple human HLA Class II DR; they are conserved
across IgG isotypes and mammalian species. In vitro and in vivo, for human PBMC and in animal models,
Tregitopes activate Tregs. Studies to delineate the mechanism of action have shown that Tregitopes’
effects are very similar to IVIg in vitro. Here we demonstrate that Tregitopes induce Tregs to produce
IL-10, leading to modulation of dendritic cell phenotype (down-regulation of Class II, CD80 and CD86
and up-regulation of ILT3), and describe the effects of Tregitopes in the ABM-TCR-transgenic skin trans-
plantation model. The discovery of Tregitopes in IgG and other autologous proteins may contribute to
improved understanding of the mechanism of action of IVIg and lead to the application of these powerful
immunomodulators to improve transplantation success and suppress autoimmune disease, in the future.
 2014 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY-NC-SA license (http://creativecommons.
org/licenses/by-nc-sa/3.0/).
1. Introduction
1.1. Tregitopes are highly conserved regulatory T cell peptide epitopes
derived from immunoglobulin that induce antigen-speciﬁc tolerance
Tregitopes have the following four characteristics: (1) their
sequences are highly conserved in similar autologous proteins;
(2) they almost all exhibit single 9-mer frames predicted by our
EpiMatrix epitope prediction algorithm to bind to at least four
different HLA DR alleles and thus are likely to be broadly
recognized in the human population; (3) in response to Tregitopes,
T cells exhibit a T regulatory phenotype (CD4+CD25+FoxP3+); and
(4) co-incubation of T cells with Tregitopes and immunogenic pep-
tides inhibits effector T cell (Teff) response to the immunogenic
peptides in vitro and suppresses antigen-speciﬁc secretion of
effector cytokines responses. Tregitope effects have been validated
in well-deﬁned animal models: NOD mice (reduction of diabetes
incidence, resolution of glucose intolerance) [1]; transplant
(induction of Tregs, signiﬁcant reduction in transplant rejection,
and allo-speciﬁc tolerance induction); and EAE (suppression of
Th17 activation and reduced disease [2]). Here we describe the
basic immunobiology of Tregitopes, and the mechanisms by which
they induce regulatory T cells to promote tolerance have yet to be
elucidated.
1.2. Natural regulatory T cells, Treg epitopes, and tolerance
Autoreactive T cells with moderate TCR afﬁnity may escape
deletion in the thymus to circulate in the periphery where
they function as ‘natural’ regulatory T cells (Treg) [3]. These
moderate-binding Treg circulate in the periphery where they
can suppress immunity against self-antigens. It has become
increasingly clear that regulatory T cells, generally characterized
as being CD4+CD25+FoxP3+, are an important component of
immune regulation in the periphery.
1.3. Are Treg epitopes present in self-proteins?
One fundamental question about Treg cells has been their
epitope-speciﬁcity. Evidence in the literature has been building
in support of self-peptides as critical ligands for promoting the
http://dx.doi.org/10.1016/j.humimm.2014.10.012
0198-8859/ 2014 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.
This is an open access article under the CC BY-NC-SA license (http://creativecommons. org/licenses/by-nc-sa/3.0/).
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development of Tregs expressing deﬁned TCRs [4–6]. Among the
self-proteins to which tolerance is acutely important for health
and homeostasis, immunoglobulins (Ig) are unique. They are
present in high concentrations in the plasma and the Ig repertoire’s
diversity and speciﬁcity are directly related to an extremely high
rate of somatic hypermutation. The presence of Treg epitopes in
the constant regions of the Fv (variable domain) and Fc (constant
domains) of immunoglobulin G (IgG) may diminish immune
response against the new ‘foreign’ sequences contained in the
complementarity determining regions (CDR) [7]. Thus, after dis-
covering highly promiscuous epitopes in Fv and Fc of IgG, we
hypothesized that these epitopes might be Treg epitopes
(Tregitopes). While we were making these initial observations,
two independent publications appeared to support our hypothesis:
Ephrem et al. showed that IVIg induced Tregs in an experimental
murine model of multiple sclerosis (EAE) [8] and Anthony and
Ravetch demonstrated the importance of antigen-processing
pathways for Treg induction by IVIg [9,10].
1.4. Potential for Tregitope therapy?
The importance of Tregs in the control of alloreactive and auto-
immune responses and maintenance of tolerance has been noted
[11]. Thus, new approaches designed to induce Tregs to be applied
for the treatment of transplant rejection, autoimmunity and
inﬂammatory diseases are active areas of investigation. IVIg is
one example of a therapy with this effect [12] and evidence is accu-
mulating that Tregitopes provide similar beneﬁcial immunomodu-
latory effects that in many respects parallel the effects of IVIg.
1.5. Validation of the Tregitope hypothesis
Within our network of Tregitope collaborations, we have
performed a number of studies to probe potential therapeutic
applications of Tregitopes in mouse models of MS (EAE) [2], cardiac
transplant (Najaﬁan et al., unpublished), Type 1 diabetes (T1D,
NOD) [1], antigen-induced airway hyper-responsiveness (Mazer
et al., unpublished), AAV-mediated gene transfer [13] and others
[14]. Together, they show that Tregitopes co-administered with
proteins suppress antigen-speciﬁc T cell and antibody responses,
and induce Treg expansion and function. Side-by-side in vivo
comparisons of Tregitope with IVIg have been performed in the
autoimmune EAE model (Khoury, Elyaman and DeGroot, unpub-
lished, and [2]) and antigen-induced allergic airway disease (Mazer
and DeGroot, unpublished), demonstrating that IVIg effects can be
replicated by Tregitope administration. More relevant to trans-
plantation, Tregitopes have been shown to induce adaptive toler-
ance to test antigens in standard models (T1D, D011.10 [1]).
Additional studies by Scott have provided striking evidence that
Tregitopes are not antigenic even when formulated in incomplete
Freund’s adjuvant (IFA) [14].
1.6. Antigen presenting cells (APC) are critical intermediaries between
antigens and lymphocytes
APC can include phagocytic cells of the monocyte/macrophage
lineage, more specialized dendritic cells (DC), and B cells that in
certain contexts have very potent antigen-presenting abilities.
APC sample peripheral antigens in the skin, gastrointestinal and
respiratory epithelia and migrate to the T cell areas of lymphoid
tissue, where they expand and activate antigen-speciﬁc helper
and killer T cells [15,16]. CD8+ and CD4+ T cells recognize MHC
I:peptide and MHC II:peptide complexes, respectively on the
surface of APC and initiate adaptive immune responses [17,18].
Beyond their antigen presenting abilities, APC integrate com-
plex soluble and cell–cell contact mediated signals in their milieu
so as to coordinate the balance between T cell tolerance and immu-
nity [15,17,19–21]. In addition to expressing MHC molecules on
their surfaces, APCs express other cell surface co-stimulatory
molecules such as CD80, and CD86 [22–24]. Higher levels of these
cell-surface co-stimulatory molecules are expressed following APC
activation that together with secretion of pro-inﬂammatory cyto-
kines and antigen presentation provide highly potent signals for
T cell activation [15,25]. The cross-talk between APC and T cells
mediated by this complex array of co-stimulatory signals shapes
downstream T cell differentiation and activation of effector
responses. In contrast, when APC present speciﬁc antigens to T
cells in the absence of supportive co-stimulation and pro-inﬂam-
matory cytokine production, these ‘tolerogenic’ APC cause cognate
T cells to differentiate towards a Treg phenotype.
We have recently developed a comprehensive hypothesis
regarding the Tregitope mechanism of action (Fig. 1). We propose
that Tregitope-speciﬁc T cells are induced when Tregitopes are nat-
urally presented on the surface of APC through degradation of IgG
or following escape from the FcRn pathway. Further, we suggest
that stimulation of Tregitope-speciﬁc Treg cells in the presence
of APC may directly down-regulate co-stimulatory signals in the
APC, resulting in a tolerogenic phenotype. We hypothesize that
presentation of Tregitopes in the context of MHC II to Treg and
activation of these Tregitope-speciﬁc Tregs are the ﬁrst steps in
the Tregitope mechanism of action, and that these peptides can
potentially be exploited to induce tolerance to a wide range of
targets including transplanted organs and tissue. Harnessing the
ability of Tregitopes to modulate effector T cell responses may lead
to new approaches to mitigate auto-reactive T cell responses in a
wide range of clinical settings.
2. Materials and methods
2.1. Tregitope and control peptides
Tregitope [26] and control peptides MOG35–55 [27] and Flu
HA306–318 [1] were synthesized by 9-ﬂuoronylmethoxy-carbonyl
(Fmoc) synthesis to a purity of >80% as determined by HPLC by
New England Peptide (Gardner, MA) and 21st Century Biochemi-
cals (Marlborough, MA). The peptide masses were conﬁrmed using
a Q-Star Nanospray Mass Spectrometer. Tregitopes are hydropho-
bic, thus lyophilized 1 mg aliquots of peptide were reconstituted
DC-Sign 
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Fig. 1. How does IVIg produce Tregitopes? Many of the effects observed for IVIg
parallel the proposed Tregitope mechanism of action. Tregitopes are peptides that
would result from IgG internalization and processing, and have been associated
with expansion of existing Tregs and induction of iTregs. Internalization of IgG
(from IVIg), presentation of Tregitope in the context of MHC Class II, and expansion
of Tregitope-speciﬁc Tregs would be consistent with recent observations that
administration of IVIG induces expansion of Tregs and IL-10 secretion in vivo, in
animals and in humans.
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by ﬁrst adding 20 ll of sterile DMSO before bringing up to volume
with complete RPMI media for cell culture or 1X PBS for injection.
All vehicle controls contained a concentration of DMSO equivalent
to the Tregitope peptide formulation.
2.2. Human peripheral blood mononuclear cell isolation
Subjects were recruited under an IRB-approved protocol in
collaboration with Clinical Partners LLC (Johnston, RI). PBMC from
individual subjects were isolated from whole blood using Ficoll
gradient separation. The buffy coat was washed in PBS and
resuspended in RPMI containing 10% human AB serum (Valley
Biomedical, Winchester, VA), 1% L-glutamine and 0.1% gentamycin
for Treg assays.
2.3. Human Treg functional assays
2.3.1. Proliferation measured by CFSE staining
Prior to culture, human PBMCs were labeled with the cell-
permeable dye (5-(and -6))-carboxyﬂuorescein diacetate, succin-
imidyl ester (CFSE, Invitrogen, Grand Island, NY) by standard
methods [28]. The cells were plated in 24-well culture plates at a
density of 2  106 viable cells/ml in 2 ml RPMI supplemented with
serum and IL-2 under the conditions of no stimulation, MOG35–55
as a negative control peptide (self, but not a Tregitope), or human
Tregitopes 167 + 289 at a ﬁnal concentration of 100 lg/ml. On day
3 of culture half of the medium was replaced with fresh RPMI sup-
plemented with serum and IL-2. Cells were harvested on day 7 and
stained with CD4, CD25, and FoxP3 as described below to quantify
Tregs within the proliferating population.
2.3.2. IL-10. Production
Human PBMCs were plated in 24-well culture plates at a den-
sity of 2  106 viable cells/ml in 2 ml RPMI supplemented with
serum under the conditions of no stimulation, MOG35–55 as a
negative control peptide, or human Tregitopes 167 + 289 at a ﬁnal
concentration of 100 lg/ml. Cultures were incubated for 72 h total,
the last 12 h in the presence of GolgiStop (BD Bioscience, San Jose,
CA) to inhibit secretion of cytokine. Upon harvest, cells were
stained for surface expression of CD4 and CD25 and intracellular
expression of FoxP3 and IL-10 as described below.
2.4. Mice
C57BL/6 female mice were obtained from The Jackson Labora-
tory and housed in pathogen-free micro-isolator cages at TGA
Sciences (Medford, MA) for the duration of these studies. All proto-
cols were approved by the Institutional Animal Care and Use Com-
mittee and conducted according to its guidelines. Where indicated,
groups of mice were immunized as shown by subcutaneous (SQ)
injection in the hind ﬂank with OVA protein emulsiﬁed in Com-
plete Freund’s adjuvant (CFA, Sigma–Aldrich, St. Louis, MO) on
days 0 and 14. Treatments were injected on days 0, 1, 2, 3; 14,
15, and 16. Treatments included a vehicle control containing a con-
centration of DMSO equivalent to the Tregitope peptide formula-
tion (SQ), mouse (m) Tregitope 167 and 289 peptides formulated
together in 1X PBS at 50 lg each per injection (SQ), or 50 mg IVIG
(Privigen, Cardinal Health, Dublin, OH) per injection (IP). Whole
spleens were harvested on day 17 and processed to generate sin-
gle-cell lymphocyte populations. Splenic leukocytes were CFSE
labeled per standard methods and placed in culture unstimulated
or stimulated with 10 lg/ml OVA antigen (Sigma, St. Louis, MO).
Cells were cultured for 72 h, harvested, and stained for surface
CD4 to determine the percent of OVA-speciﬁc CD4 T cell
proliferation.
The ABM-tg model [29,30] is a B6/Thy1.2+ TCR-tg mouse model
with CD4+ T cells that express a TCR with deﬁned speciﬁcity
against the bm12 antigen (ABM-tg). These mice were mated with
FoxP3 GFP reporter mice to generate ABM-Foxp3GFP TCR-tg mice
and the colony was maintained in the Brigham and Women’s
Animal Facilities [31,32]. Typically, >90% of CD4+ T cells express
the tg TCR, and approximately 2% of CD4+ T cells are GFP+. ABM-
Foxp3GFP TCR-tg T cells were ﬂow-sorted into GFP+ or GFP pop-
ulations to >98% purity. GFP+ or GFP cells (0.6  106 cells) were
adoptively transferred into congenic WT B6/Thy1.1+ recipient
mice. One day later, recipients received skin transplants from C-
H-2bm12/KhEg (bm12) donors obtained at the age of 6–8 weeks
from the Jackson Laboratory). Recipients were treated with mTreg-
itope 289 or a FluHA negative control peptide on the day of adop-
tive transfer (100 lg, Day 0), and 50 lg on days 2, 4, and 6. On day
7 following transplantation, draining lymph nodes (dLNs) were
harvested from recipient mice and processed into single cell sus-
pensions by standard methods. Proportions of donor bm12-speciﬁc
Thy1.2+CD4+ T cells that were GFP+ (FoxP3+ Treg) or GFP (FoxP3
effector T cells) were monitored post-transplantation by ﬂow
cytometry and distinguished from recipient cells that were
Thy1.1+.
2.5. Flow cytometry
Cells were surface or intracellularly stained according to stan-
dard protocols [28]. For antigen presenting cell (APC) phenotyping,
cells were stained with anti-human CD11c (eBioscience, Clone 3.9),
anti-mouse CD11b (eBioscience, Clone M1/70), anti-human HLA-
DR, DP, DQ (BD Biosciences Clone Tu39), anti-mouse pan-MHC II
(eBioscience, Clone M5/114.15.2), anti-human CD80 (BioLegend,
Clone 2D10), anti-mouse CD80 (BioLegend, Clone 16-10A1), anti-
human CD86 (BioLegend IT2.2), anti-mouse CD86 (eBioscience,
Clone GL1), and human anti-ILT3 (eBioscience, Clone ZM4.1).
Human Treg cells were identiﬁed by the combination of anti-
human CD4 (eBioscience, Clone OKT4), anti-human CD25 (eBio-
science, Clone BC96), and anti-human FoxP3 (eBioscience, Clone
236A/E7). Treg functions were studied by combining this panel
with CFSE (Invitrogen) for proliferation or with anti-human IL-10
(eBioscience, Clone JES3-9D7) for cytokine production. OVA-spe-
ciﬁc effector T cells were surface stained with CD4 (eBioscience
RM4-4) to determine the proportion of CD4 T cells that proliferated
(CFSE low) in response to OVA stimulation ex vivo. Cells were
acquired on a FacsCalibur Flow Cytometer equipped with an
optional argon laser and CellQuest software (Becton Dickenson,
San Jose, CA), and analyzed using FlowJo Software (Tree Star,
Ashland, OR).
3. Results
3.1. Tregitopes stimulate Treg proliferation
Previous studies had demonstrated increased proportions of
FoxP3+ Tregs within the CD4+CD25+ population upon Tregitope
exposure [26]. To expand upon these ﬁndings, we set out to deter-
mine whether Tregitopes stimulated Treg proliferation. Human
PBMCs were labeled with CFSE dye before culture with media,
100 lg/ml negative control peptide (MOG35–55), or 100ug/ml
hTregitopes 167 + 289 for 7 days in the presence of 10 ng/ml IL-2.
At the conclusion of the culture, cells were stained for intracellular
expression of FoxP3 [33] and surface expression of CD4 and CD25.
CD4+ T cells that had divided were identiﬁed by ﬂow cytometry as
those exhibiting dilution of CFSE dye; these were analyzed for
CD25 and FoxP3 (Fig. 2). Among those CD4 T cells that had
proliferated, Tregitope-exposed cultures exhibited increased
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proportions with a Treg (CD25+FoxP3+) phenotype when compared
to media- or control peptide (Fig. 2B). These data support the
hypothesis that MHC Class II-binding Tregitopes stimulate Tregi-
tope-speciﬁc CD4+ T cells with surface molecules consistent with
a Treg phenotype to proliferate.
3.2. Tregitope-mediated induction of IL-10
One attribute of activated Treg demonstrated by this group and
others is the production of IL-10 [26,34,35]. Therefore we asked
whether Tregitope exposure led Tregs to express this key cytokine
associated with tolerance induction. Human PBMCs were
incubated with media alone, MOG35–55 peptide (100 lg/ml), or
hTregitopes 167 + 289 (100 lg/ml). Cells were incubated for 72 h,
the last 18 h in the presence of the protein transport inhibitor Gol-
giStop, Cells were harvested and subjected to intracellular staining
for IL-10 together with FoxP3 and surface staining for CD4 and
CD25. Flow cytometric analysis was used to gate on the CD4+CD25+
cells (data not shown) within which the FoxP3+ Treg population
could be examined for IL-10 expression. When the CD4+CD25+ T
cells were examined for expression of IL-10 and FoxP3, it was con-
ﬁrmed that Tregitope exposure increased the proportion of Treg
that expressed IL-10 (Fig. 3).
3.3. Effects of Tregitopes on APC phenotype
CD80, CD86, and MHC Class II expression by APC are critically
important contributors to the balance of Treg and T effector cell
responses. Moreover, evidence in the literature indicated that
these co-stimulatory molecules were down-modulated in response
to a Tregitope-like peptide [36] and IVIG [37]. We therefore mea-
sured the expression of these surface molecules after Tregitope
treatment, postulating that their modulation might contribute to
the mechanism(s) by which Tregitopes induce tolerance. Mouse
splenic leukocytes or human PBMCs were incubated with media
alone, a negative control peptide, or Tregitopes. Cells were col-
lected at 24, 48, or 72 h for surface marker staining and ﬂow
cytometry analysis. In the example shown here, mouse splenic
APCs (CD11b+) incubated with murine Tregitopes 167 + 289 for
72 h exhibited decreased expression of MHC II (46% decrease),
CD80 (59% decrease) and CD86 (36% decrease) as compared to cells
incubated with media alone (Fig. 4). As an additional negative con-
trol, cells were incubated with peptide that also binds to murine
MHC. Neither control (neither media nor Flu306–318 peptide) caused
decreases in CD80, CD86 or MHC II. The shift towards a tolerogenic
phenotype was only observed when murine (Fig. 4) or human
PBMCs (data not shown) were incubated with respective murine
or human Tregitopes 167 + 289 for 72 h. Moreover, these changes
were not evident at 24 or 48 h, suggesting that the shift in the
APC phenotype was secondary to other, primary Tregtiope-medi-
ated events taking place in the culture, such as the activation of
Tregs as described in Sections 3.1 and 3.2 above.
As further conﬁrmation that Tregitope exposure was skewing
the phenotype of APCs in these cultures, we examined expression
of a marker that has been positively associated with tolerance
induction. ILT3 is a receptor expressed by APCs that has been
shown to negatively regulate activation and can be used for
antigen uptake [38]. In human APC, intracellular signaling
Fig. 2. Tregitopes stimulate Treg proliferation. Human PBMCs were labeled with CFSE and incubated with media alone, control MOG35–55 (100 lg/ml), or hTregitopes
167 + 289 (100 lg/ml total) in the presence of IL-2. Cells were fed fresh media + IL-2 on day 3 and harvested on day 7. Cells were stained for CD4, CD25, and FoxP3. The gating
strategy was based on CD4+ T cells that were CFSE low, indicating proliferation, then analyzed for CD25 vs isotype control (A) or CD25 vs FoxP3 (B). The proportions of
proliferating CD4 T cells that express the Treg phenotype (CD25+FoxP3+, upper right quadrant) are indicated; increases in proliferating Treg were observed with Tregitope
(right) as compared to either media (left) or MOG peptide (center) controls.
Fig. 3. Tregitopes stimulate IL-10 in Tregs. Human PBMCs were incubated for 72 h with media, control MOG35–55 (100 lg/ml), or hTregitopes 167 + 289 (100 lg total). Cells
were stained for intracellular IL-10 and T cell markers CD4, CD25, and FoxP3. After gating on CD4+CD25+ cells, dot-plots display %IL-10+ FoxP3+ cells (upper right quadrant).
Increased proportions of IL-10+ Treg were observed upon Tregitope exposure (right) in contrast to media (left) or MOG (center).
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downstream of ILT3 inhibits NF-kappa B activation and the
transcription of costimulatory molecules to promote anergy and
regulatory function in T cells with cognate speciﬁcity [39]. Human
PBMCs were cultured for 72 h with media alone, MOG35–55 peptide
(100 lg/ml), or human Tregitopes 167 + 289 (100 lg/ml). At the
conclusion of the culture, cells were collected and stained for
CD11c and ILT3. Examination of ILT3 on the surface of the
CD11c+ population indicated that expression remained low under
conditions of media alone or MOG35–55 negative control, but there
was a measurable induction in the presence of Tregitopes (Fig. 5).
These results provided further evidence that Tregitopes, either
directly or indirectly, were promoting a tolerogenic APC
phenotype.
3.4. Tregitopes recapitulate effects of IVIg to suppress antigen-speciﬁc
T cell responses
To further support our hypothesis that Tregitopes promote tol-
erance induction like the known immunomodulator IVIg, we
sought to directly compare their ability to modulate in vivo anti-
gen-speciﬁc T cell responses. Thus we established a basic model
of OVA immunogenicity adapted from Aubin et al. in which admin-
istration of OVA antigen elicits a robust, systemic speciﬁc T cell
response that is suppressed in mice administered IVIg [40]. To
stimulate OVA-speciﬁc responses, mice were administered OVA
formulated in CFA by subcutaneous (SQ) injection on days 0 and
14. Mice were treated on days 0, 1, 2, 3; 14, 15, and 16 with vehicle
control (SQ), mouse Tregitope 167 and 289 peptides formulated
together in saline at 50 lg each per injection (SQ), or 50 mg IVIg
per injection (IP). Splenic leukocytes were harvested on Day 17,
CFSE labeled, and cultured in the presence of whole OVA Ag for
72 h. At the conclusion of the culture, cells were harvested and
co-stained for CD4. After gating on the CD4+ T cells, the proportion
of CFSE low cells within the CD4+ subset was used to quantify the
proportion of CD4 T cells that proliferated in response to OVA Ag ex
vivo. Averages of 12 mice per group pooled from three individual
experiments are shown ± standard error (Fig. 6). In mice treated
with IVIg, OVA-speciﬁc CD4 T cell proliferation was decreased
Fig. 4. Effects of Tregitopes on APC Phenotype. Mouse splenic leukocytes were incubated with media alone, Flu306–318 at 100 lg/ml as control, or mTregitopes 167 + 289 at
100 lg total. Cells were harvested after 72 h and stained for the APC marker CD11b, and the costimulatory markers CD86, CD80, and MHC II. Histograms depict surface
expression of CD86, CD80, and MHC II on Tregitope-exposed CD11b populations (blue, isotype control in red); the percent positive within the selected region is indicated in
the upper right. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. Tregitope-mediated induction of ILT3. Human PBMC were incubated for 72 h with media, control MOG35–55 (100 lg/ml), or hTregitopes 167 and 289 (100 lg total).
Cells were stained for CD11c and ILT3. After gating on CD11c+ cells (left), histograms were derived that display the proportion of ILT3+ cells within the CD11c+ population.
Increased proportions of ILT3+ APCs were observed upon Tregitope exposure (blue) relative to MOG (black). (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
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relative to vehicle control, recapitulating the original Aubin exper-
iment [40]. As postulated, Tregitope treatment also resulted in the
signiﬁcant inhibition of OVA-speciﬁc CD4 T cell proliferation as
compared to vehicle-treated mice. The magnitude of the IVIg and
Tregitope effects on CD4 T cell proliferation was comparable,
however the effective dose of Tregitope to achieve this effect was
signiﬁcantly decreased: Tregitopes were administered as a 50 lg/
injection relative to IVIg that was administered at 50 mg/injection.
3.5. Tregitopes promote expansion of alloreactive Tregs and induce
graft-reactive iTregs in vivo
The capacity of Tregs to modulate adaptive and innate immune
responses has led to their investigation for use in novel strategies
to regulate allogeneic T cell responses. We believe that Tregitopes,
by expanding Tregs, are capable of regulating alloimmune
responses. This hypothesis was tested in mice transgenic for a
TCR speciﬁc for bm12 antigen crossed with mice expressing GFP
under control of the FoxP3 promoter (ABM-Foxp3GFP) [31,32]. In
these mice, typically >90% of CD4+ T cells express the transgenic
TCR, and approximately 2% of CD4+ T cells are GFP+. Moreover,
ABM-Foxp3GFP CD4+ cells express CD90.2 (Thy1.2+) to distinguish
them from recipient CD4 T cells that are Thy1.1+. Donor
ABM-Foxp3GFP CD4 T cells were isolated by ﬂow cytometry,
sorting for GFP+ or GFP populations with >98% purity. These
Thy1.2+-FoxP3+GFP+ or Foxp3GFP cells (0.6 106) were adoptively
transferred into Thy1.1 B6 recipients 1 day prior to bm12 skin
transplantation. Recipients were treated with Tregitope 289 or a
FluHA negative control peptide on the day of adoptive transfer
(100 lg, Day 0), and 50 lg on days 2, 4, and 6 (Fig 7A). In Tregi-
tope-treated mice that received CD4+Thy1.2+GFP+ donor Treg cells,
signiﬁcant increases in the CD4+Thy1.2+GFP+Treg populations were
observed relative to controls (Fig 7B) indicating that transferred
FoxP3+ Tregs were expanding. For Tregitope-treated recipients of
CD4+Thy1.2+GFP cells, increased numbers of CD4+Thy1.2+GFP+
populations (Fig 7C) demonstrate that the ABM-Tg CD4+Thy1.2+
GFP cells that were transferred were induced in vivo to express
FoxP3, suggesting the induction of antigen-speciﬁc Tregs in the
presence of Tregitope. Moreover, Tregitope-treated mice exhibited
fewer donor-derived FoxP3 Teffector-memory cells (Thy1.2+CD4+
CD44highCD62Llow) than controls (Fig 7D) indicating that Tregitope
treatment was associated with suppression of ABM12-speciﬁc T
cell responses. Taken together, these data indicate that Tregitopes
promote expansion of Tregs as well as induce adaptive Tregs.
4. Discussion
We present here direct evidence that upon MHC II-mediated
presentation to Tregs, Tregitopes stimulate the activation of Tregs
as demonstrated by proliferation and IL-10 production (Figs. 2 and
3), promote a tolerogenic APC phenotype (Figs. 4 and 5), and mod-
ulate antigen-speciﬁc effector T cell responses in vivo (Figs. 6 and
7). These data support our working hypothesis for the mechanism
of action (Fig. 8) whereby Tregitope effects are initiated upon APC/
MHC II-mediated presentation to a population of regulatory T cells
speciﬁc for self-IgG-derived epitopes. Tregs that recognize
Tregitopes presented in the context of MHC II become activated,
produce IL-10, and interact with the APC to reinforce the develop-
ment of a tolerogenic phenotype. These tolerogenic APC and/or
Treg act on local antigen-speciﬁc Teff to suppress their effector
responses.
4.1. Tregitopes may provide a safer alternative to IVIG
Many adverse effects (AEs) associated with IVIG administration
are mild and transient. Though rare, more severe AEs include acute
renal failure, thromboembolic events, skin-related effects includ-
ing toxic epidermal necrolysis and aseptic meningitis [41,42].
Patients also report generalized asthenia, nausea and vomiting.
Poor tolerance of weekly IVIg infusions limits its use in some auto-
immune diseases [43]. In general however, IVIg is considered rela-
tively safe. Thus the main incentives to seek alternatives to IVIg are
to conserve the limited supply for patients with primary immun-
odeﬁciencies for whom this is the only option, and to reduce
adverse events associated with IVIg treatment. Since Tregitopes
replicate the tolerogenic effects of IVIg in vitro and in vivo where
those effects are Treg-mediated, Tregitopes might serve as a safe
therapeutic alternative to IVIG for certain conditions, like induction
of transplant tolerance and suppression of autoimmunity.
4.2. Tregitope applications in transplant
Organ transplantation remains the therapy of choice for the
majority of patients with end-stage organ failure. Traditional
immunosuppressive regimens rely on agents which cause general
suppression of the adaptive immune response and are conse-
quently associated with various undesirable related side-effects
including opportunistic infections and malignancies. The achieve-
ment of robust and reproducible transplantation tolerance by
clinically applicable and safe therapeutic regimens is, therefore, a
major goal in transplantation research. The discovery of Tregitopes
in IgG may allow clinicians to safely harness the therapeutic poten-
tial of Tregs to modulate immune responses while avoiding admin-
istration of immunoglobulin therapy. They have vast potential as a
unique and novel pro-tolerogenic therapy that, used alone or in
combination with costimulatory blockade, may induce tolerance
in the context of transplantation.
4.3. Additional Tregitope applications
Replacement of a pooled-donor, blood-derived product for
which the mechanism of action is not certain with a therapeutic
product for which the Active Pharmaceutical Ingredient (API) is
precisely deﬁned, would represent a major step forward for the
ﬁeld of autoimmune disease therapy. If the induction of regulatory
T cells by IVIG can be attributed to Tregitopes, then a number of
autoimmune diseases for which IVIG therapy is currently used,
on-label and off, may be appropriate targets for immunomodula-
tory formulations that only contain Tregitope peptides. Two exam-
ples of disease in which IVIG is the predominant immunotherapy
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Fig. 6. Tregitope exposure in vivo suppresses antigen-speciﬁc T cell proliferation ex
vivo. Splenic leukocytes from mice immunized with OVA and treated with vehicle,
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After gating on the CD4+ T cells, analysis of CFSE low cells indicates the proportions
of CD4 T cells that proliferated in response to OVA Ag ex vivo. Averages of 11–12
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include Chronic Inﬂammatory Demyelinating Polyneuropathy
(CIDP) and Multifocal Motor Neuropathy (MMN). Introduction of
Tregitopes as alternatives to IVIG would also have a dramatic
impact on the demand for IVIG for immune modulation therapy
[9,44,45]. IVIG also acts rapidly and effectively in Immune Throm-
bocytopenic Purpura (ITP), Kawasaki Syndrome (KS), polymyositis,
dermatomyositis, neurological syndromes such as Guillain–Barré
and CIDP, cases of severe steroid-dependent asthma, and many
others [44,45]. Tregitope-peptide therapy may be an attractive
alternative the systemic immune suppression treatments that are
sometimes used for those conditions.
4.4. Potential for Tregitope-mediated antigen-speciﬁc tolerance
induction
As Tregitopes appear to be able to induce antigen-speciﬁc toler-
ance (induced Tregs that are speciﬁc to co-administered proteins),
the possibility of tailoring the Tregitope therapy to speciﬁc autoim-
mune diseases would represent an additional advantage for clinical
applications. One could envision allergen-speciﬁc treatments using
combinations of Tregitopes and allergen proteins or peptides, and
treatment for autoimmune diseases such as diabetes, that would
rely on co-administration of Tregitope and diabetes antigens. The
idea of speciﬁcally generating MOG-reactive Treg cells is also
particularly attractive for the therapy of MS where, based on our
data in the EAE mouse model, we believe that Tregitopes induce
antigen-speciﬁc adaptive tolerance. Tregitopes may have even
broader applications in protein therapeutics, animal health, and
blood factor or enzyme replacement therapy.
4.5. Moving Tregitope towards the clinic
Treatment of many autoimmune diseases relies on immunosup-
pressive therapy rather than on treatments directed toward restor-
ing a balance between effector and regulatory immune responses.
Given that Tregitope peptides appear to induce adaptive tolerance
in a mouse model, the next consideration is to evaluate the optimal
formulation and determine the best time course of the tolerance
induction, in addition to measuring the duration of response, the
dose required, the safety and toxicity of the treatment (vis-à-vis
other immune responses) and optimal formulation/route of admin-
istration. Our preliminary studies suggest that adaptive tolerance
induction may be within reach, raising hopes that we may be on
the right path for the development of an effective immunotherapy
based approach to autoimmune disease.
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